about
Review of olanzapine in the management of bipolar disordersElucidating the role of neurotensin in the pathophysiology and management of major mental disorders.Schizophrenia proteomics: biomarkers on the path to laboratory medicine?Characterization of binding and inhibitory properties of TAK-063, a novel phosphodiesterase 10A inhibitorInfluence of CYP2D6 polymorphisms on symptomatology and side-effects of patients with schizophrenia in MalaysiaSexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone.Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 10A inhibitor, PDM-042 [(E)-4-(2-(2-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)vinyl)-6-(pyrrolidin-1-yl)pyrimidin-4-yl)morpholine] in rats: potAntipsychotic drug toxicology in children.Neuroprotection of paliperidone on SH-SY5Y cells against β-amyloid peptide(25-35), N-methyl-4-phenylpyridinium ion, and hydrogen peroxide-induced cell death.Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation.TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia.Brain PET measurement of PDE10A occupancy by TAK-063, a new PDE10A inhibitor, using [11 C]T-773 in nonhuman primates.Combined treatment with a selective PDE10A inhibitor TAK-063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic-like effects without affecting plasma prolactin levels and cataleptic responses in rodents.Acupuncture as Add-On Treatment of the Positive, Negative, and Cognitive Symptoms of Patients with Schizophrenia: A Systematic Review.
P2860
Q24657398-4303E2E4-0863-420E-9996-7BA1BF05EDAEQ30426586-575C0D67-4A7B-44D7-A278-0B6F2150CE8EQ34973585-2578B767-1863-45B1-A378-97BCAE0B5049Q35588358-87133DE4-C95B-4433-9997-85CEDA6D0A60Q35896386-BD66C021-23A8-4D83-B772-337F61A629E9Q37224571-2D98BA70-9636-41AC-9FE1-E7AC05CD2DCCQ37591807-9E9F36A4-B19F-4532-8806-CEC9BE9941CFQ37852719-5A84E15E-018E-472C-9289-4FAC27B0D301Q39552320-E5A7DF3F-E8A6-4451-9087-9F350E081582Q43258119-C5C76FB1-B62D-45F6-8D7B-8844C1F6169BQ48272772-4D933E29-BFBC-42C0-977C-1C55A7CA999CQ48906405-8884ECAB-CDC2-4164-8726-07A93F2EE507Q50124634-E76C5740-4CBA-4339-B406-18E5B66BC9D1Q53422296-009C590F-0D28-4A92-90D9-746183A5106E
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Current schizophrenia drugs: efficacy and side effects.
@ast
Current schizophrenia drugs: efficacy and side effects.
@en
type
label
Current schizophrenia drugs: efficacy and side effects.
@ast
Current schizophrenia drugs: efficacy and side effects.
@en
prefLabel
Current schizophrenia drugs: efficacy and side effects.
@ast
Current schizophrenia drugs: efficacy and side effects.
@en
P2093
P2860
P1476
Current schizophrenia drugs: efficacy and side effects.
@en
P2093
Axel Hinzpeter
Karolina Leopold
Martin Schaefer
Michael Krebs
P2860
P304
P356
10.1517/14656566.7.8.1005
P407
P577
2006-06-01T00:00:00Z